InvestorsHub Logo
Followers 5
Posts 2568
Boards Moderated 0
Alias Born 11/03/2019

Re: None

Thursday, 09/30/2021 12:41:15 PM

Thursday, September 30, 2021 12:41:15 PM

Post# of 3749
$ATRX Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, today provides shareholders an update on corporate strategy and planned clinical development of MLR-1019 (armesocarb) and MLR-1023 (tolimidone). On July 29, 2021 and August 24, 2021, respectively, the Company announced executing exclusive license agreements for MLR-1019 for Parkinson’s disease (PD) and MLR-1023 for Type 1 diabetes.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ATRX News